de-Torres, JP, Casanova, C, Marín, JM, Cabrera, C, Marín, M, Ezponda, A, Cosio, BG, Martínez, C, Solanes, I, Fuster, A, Calle, M, Gotera, C, Feu-Collado, N, Marin, A, Alcaide, AB, Sangro, M, Bastarrika, G, Celli, BR. Impact of Applying the Global Lung Initiative Criteria for Airway Obstruction in GOLD Defined COPD Cohorts: The BODE and CHAIN Experience. ARCHIVOS DE BRONCONEUMOLOGIA. 2024; 60(1)DOI:10.1016/j.arbres.2023.10.002. PMID:37925245. IF:9.200(Q1/1D).

Betancor, D, Otal, M, Olaguibel, JM, Rodrigo-Muñoz, JM, Puebla, MJA, Arismendi, E, Barranco, P, Barroso, B, Bobolea,, Cárdaba, B, Cruz, MJ, Curto, E, Del Pozo,, Domínguez-Ortega, J, González-Barcala, FJ, Luna-Porta, JA, Martínez-Rivera, C, Mullol, J, Muñoz, X, Picado, C, Plaza,, Quirce, S, Rial, MJ, Roibás-Veiga,, Soto-Retes, L, Valero, A, Valverde-Monge, M, Sastre, J. Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2024; 34(3)DOI:10.18176/jiaci.0966. PMID:38888581. IF:4.800(Q1/1D).

Plaza, V, Trigueros, JA, Carretero, JA, Arranz, IO, Chicote, JMV, Sánchez, CA, Tomás, JB, Serrano, CC, Juncal, LD, Domínguez-Ortega, J, Rivero, JF, Campos, JGS, Fernández, EM, Martinez, S, Lacomba, JM, Quirce, S. Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2024; 34(4)DOI:10.18176/jiaci.0975. PMID:38334050. IF:4.800(Q1/1D).

Shachar, SS, Korzets, Y, Shepshelovich, D, Zlothover, N, Amir, E, Tibau, A, Goldvaser, H. Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review. CANCER TREATMENT REVIEWS. 2024; 122DOI:10.1016/j.ctrv.2023.102666. PMID:38064877. IF:10.500(Q1/1D).

Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, C, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Onkourologiya. 2024; 20(1)DOI:10.17650/1726-9776-2024-20-1-24-35. PMID:. IF:(Q/D).

León X., Neumann E., Holgado A., Vásquez R., Pujol A., Quer M.. Oncological results of salvage treatment in patients with oropharynx carcinoma treated with radiotherapy. Acta Otorrinolaringologica Espanola. 2024; 75(1)DOI:10.1016/j.otorri.2023.01.002. PMID:. IF:(Q/D).

Benjumea, C, Navarro, F, Tarrés, CA. Improving the diagnosis of urinary tract infections by the use of enriched media and a 48-hour incubation period. JOURNAL OF MEDICAL MICROBIOLOGY. 2024; 73(6)DOI:10.1099/jmm.0.001846. PMID:38935081. IF:2.000(Q3/8D).

Habib, AA, Sacconi, S, Antonini, G, Cortés-Vicente, E, Grosskreutz, J, Mahuwala, ZK, Mantegazza, R, Pascuzzi, RM, Utsugisawa, K, Vissing, J, Vu, T, Wiendl, H, Boehnlein, M, Greve, B, Woltering, F, Bril, V. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study. Therapeutic Advances in Neurological Disorders. 2024; 17DOI:10.1177/17562864241273036. PMID:39297052. IF:4.100(Q1/2D).